Protagenic Therapeutics, Incnew 8-K filings

Protagenic Therapeutics reports no clinically-relevant adverse events in the single-dose portion of its Phase 1 trial for PT00114, a stress-regulating peptide.

Protagenic Therapeutics has successfully regained compliance with Nasdaq's minimum bid price requirement, resolving a potential delisting issue.